Mechanisms and kinetics of bacterial clearance after experimental 1

colonisation in adults with asthma 2

- 3 *Seher Raza Zaidi MRCP^{1,2}, *Simon P. Jochems PhD^{1,3}, *Jesús Reiné PhD¹, Sherin Pojar MSc^{1#},
- Elissavet Nikolaou PhD^{1#}, Elena Mitsi PhD¹, Esther L. German¹ Angela D. Hyder-Wright MSc 4
- ^{1,2,4}, Hugh Adler PhD^{1,2}, Helen Hill PhD^{1,2}, Caroline Hales PhD^{1,2}, Victoria Connor MD^{1,2}, Carla 5
- Solórzano PhD¹, Stephen B. Gordon PhD^{1,4,5}, John Blakey PhD⁶, David Goldblatt PhD⁷, 6
- ^Daniela M. Ferreira PhD¹, ^Jamie Rylance PhD^{1,5} 7
- 8 *Joint first authors
- 9 ^Joint senior authors
- 10 [#]Contributed equally
- 11 1. Liverpool School of Tropical Medicine
- **Pembroke Place** 12
- Liverpool 13
- 14 L3 5QA
- 15 2. The Royal Liverpool University Hospital
- 16 **Prescott Street**
- Liverpool 17
- 18 L7 8XP

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 19 3. Center for Infectious Diseases,
- 20 Leiden University Medical Center,
- 21 Albinusdreef 2, 2333 ZA Leiden,
- 22 Netherlands
- 23 4. Clinical Research Network, Northwest Coast, Liverpool
- 5. Lung Health Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme,
- 25 Blantyre, Malawi
- 26 6. Respiratory Medicine, Sir Charles Gairdner Hospital Perth, WA, Australia
- 27 7. Great Ormond Street, Institute for Child Health, 30 Guilford Street, Holborn, London
- 28 WC1N 1EH
- 29 Corresponding Author:
- 30 Dr Jamie Rylance
- 31 Clinical Sciences Department
- 32 Liverpool School of Tropical Medicine
- 33 Pembroke Place
- 34 Liverpool
- 35 L3 5QA Phone: Fax:
- 36 jamie.rylance@lstmed.ac.uk
- 37 Prof Daniela Ferreira

- 38 Clinical Sciences Department
- 39 Liverpool School of Tropical Medicine
- 40 Pembroke Place
- 41 Liverpool
- 42 L3 5QA Phone: 0151 705 3711
- 43 Daniela.ferreira@lstmed.ac.uk
- 44

- 46 Author Contributions
- 47 SZ Study design, Manuscript writing and drafting, data analysis and interpretation, performing
- 48 procedures and recruitment
- 49 SJ Study design, manuscript writing and drafting, sample processing, data analysis and
- 50 interpretation
- 51 JRe Manuscript writing and drafting, sample processing, data analysis
- 52 SP Manuscript writing and drafting, sample processing
- 53 EN Manuscript writing and drafting, sample processing
- 54 EM Manuscript writing and drafting, sample processing
- 55 EG Manuscript writing and drafting, sample processing
- 56 AW Manuscript writing and drafting and assisting in procedures

- 57 HA Manuscript writing and drafting, recruitment
- 58 HH Manuscript writing and drafting, recruitment
- 59 CH Manuscript writing and drafting, recruitment
- 60 VC Manuscript writing and drafting, recruitment
- 61 CS Manuscript writing and drafting, sample processing
- 62 SG Study design, funding, manuscript writing and drafting
- 63 JB Study design, manuscript writing and drafting
- 64 DG Data analysis and interpretation
- 65 DF Study design, funding, manuscript writing and drafting, data analysis and interpretation
- 66 JR Study design, manuscript writing and drafting, performed procedures

67 Funding:

The project was funded by MRC programme grant (MR/M011569/1) to SG, and Bill and Melinda Gates Foundation (grant OPP1117728). Flow cytometric acquisition was performed on a BD LSR II cytometer funded by a Wellcome Trust Multi-User Equipment Grant (104936/Z/14/Z).

72 Conflict of Interest:

73 The authors of this study do not have any disclosures or conflict of interests to declare

75 Word Count:

76 2319

78 Abstract

79 Background

Pneumococcal pneumonia is a leading cause of death, particularly affecting those with
 chronic respiratory disease. Observational studies suggest increased nasopharyngeal
 colonisation rates with *S.pneumoniae* in asthma, and lower specific antibody levels.

83 Objectives

Using experimental human pneumococcal challenge, we examined the acquisition and kinetics of nasopharyngeal colonisation of *Streptococcus pneumoniae* serotype 6B. We also aimed to dissect associated mucosal and systemic immune responses and immunizing effect of carriage.

88 Methods

Fifty participants with asthma well-controlled on moderate inhaled corticosteroid doses were challenged with pneumococcus, and a subset of colonized individuals were re-challenged 6-11 months later with the same pneumococcal isolate . Colonisation rates (from nasal wash), systemic antibody levels and mucosal cellular and cytokine responses were compared to 151 healthy controls.

94 Measurements and Main Results

Colonisation rates were 28/50 (56%) and 68/151 (45%) in those with asthma and controls respectively, p=0.17. Duration of colonisation was shorter in people with asthma (median 14 days vs 29 days, p=0.03) but of similar density. Body mass index was higher in colonised compared with non-colonised asthma individuals (median 24.7 [IQR 24.1-29.0] and 23.5 [20.1-26.4] respectively, p=0.019). Despite an increase in pneumococcal capsular and protein

antibodies after colonisation, 4/12 asthmatic individuals became colonised again upon rechallenge. Nasal neutrophil and T cell levels, in particular mucosa associated invariant T (MAIT) cells were decreased in people with asthma compared to healthy controls (median 9.4, [IQR 5.0-13.3 %] of CD8⁺ T cells) vs median 15.8, [IQR 9.9-25.9 %] of CD8⁺ T cells respectively (p=0.0047). Most nasal cytokines were also reduced in asthmatics. In both groups, colonisation led to recruitment of monocytes and granulocytes to the nasal mucosa.

106 Conclusions:

107 Nasopharyngeal colonisation was of shorter duration in those with asthma compared to 108 controls, although acquisition rates were not different. Rates of colonisation were higher with 109 increasing BMI in individuals with asthma. Despite a baseline reduction in mucosal immune 110 cells and cytokines in asthmatics with corticosteroids, colonisation led to cellular recruitment 111 in both groups. Colonisation was not associated with protection from homologous re-112 challenge in individuals with asthma, in contrast to healthy volunteers.

113 Clinical Implication: (single sentence)

People with asthma on inhaled corticosteroids have an increased likelihood of pneumococcal
 infection secondary to reduced mucosal immune responses from nasopharyngeal
 colonisation and a lack of protection from re-exposure.

117 Abstract word count: 250

118 Key Messages:

• Duration of experimental pneumococcal colonisation is reduced in asthma

120	٠	A high BMI increases the likelihood of experimental pneumococcal colonisation in
121		asthma
122	•	Rate and density of pneumococcal colonisation is similar in people with asthma
123		compared to healthy controls
124	•	Pneumococcal colonisation does not confer protection against re-challenge in asthma,
125		despite boosting antibody titres against pneumococcal proteins and capsule
126	٠	Mucosal immune cells and cytokine levels are reduced in asthmatic individuals with
127		inhaled corticosteroids compared to healthy controls.
128	•	There is recruitment of monocytes into the nasal mucosa following colonisation in
129		people with asthma, with reduced nasal neutrophils and T cells, specifically Mucosal
130		Associated Invariant T (MAIT) cells, in comparison to healthy controls.
131		

132 Capsule Summary:

Epidemiological studies show that people with asthma are more likely to have nasal colonisation with *S. pneumoniae*, which may proceed to infection such as pneumonia and invasive pneumococcal disease. This study investigates the mechanisms underlying pneumococcal colonisaion and its effect on subsequent pneumococcal encounters.

137 Key words:

Asthma, immunology, mucosal immune response, obesity, experimental nasopharyngealpneumococcal colonisation, BMI

140 **Abbreviations:**

- 141 ACT score Asthma Control Test
- 142 BDP BudesonidePropionate Equivalent
- 143 BMI Body Mass Index
- 144 CFU; colony forming unit
- 145 EHPC Experimental human pneumococcal challenge
- 146 FEV2;Forced expiratory volume second
- 147 FeNO fractional Exhaled Nitric Oxide
- 148 ICS; Inhaled corticosteroids
- 149 IQR; inter quartil range
- 150 MAIT mucosa associated invariant T cells
- 151 MSD- Meso Scale Discovery
- 152 PBMC, Peripheral blood mononuclear cells
- 153 PEFR; Peak expiratory flow rate
- 154

155 Introduction

156 Streptococcus pneumoniae is the most common cause of bacterial pneumonia. Large scale 157 real-world observational data shows people with asthma on inhaled corticosteroids (ICS) are 158 at increased risk of pneumonia in a dose-dependent manner 1^{-3} , though this relationship was 159 not observed in manufacturers' retrospective analysis of randomised clinical trials. Epidemiologically, asthma is associated with an increased prevalence of nasopharyngeal 160 colonisation by *S. pneumoniae* ⁴⁻⁷, although information on density and duration are lacking. 161 162 An Italian cross-sectional study reported a 45% colonisation rate in children and adolescents with asthma ⁴ and nasopharyngeal swabs from Finnish army recruits identified those with 163 asthma twice likely to be colonised with *S.pneumoniae*⁸. Mucosal cellular mechanisms are 164 165 important for clearance of nasopharyngeal colonisation of *S. pneumoniae*⁹, and an 166 impairment of these may lead to increased colonisation and perhaps acute infection such as pneumonia and invasive pneumococcal disease ¹⁰. Airway inflammation in asthma, and ICS 167 therapy, alter mucosal immune responses ¹¹⁻¹³. Routine immunisation against pneumococcus 168 is offered to people with chronic respiratory disease and those deemed immune 169 170 compromised secondary to treatment with oral corticosteroids in the United Kingdom and United States ^{1, 4, 5}. 171

We hypothesise that the immunological containment of pneumococcal colonisation is altered in asthma due to the condition itself, or secondary to ICS and that altered mucosal dynamics of colonisation mediate susceptibility to disease. We used an established human challenge model ^{14, 15} to determine factors underlying susceptibility to pneumococcal colonisation in people with asthma and healthy controls ^{16, 17}.

177 Methods

178 Study Design

We recruited 50 participants, from June 2016 until April 2018, aged 18-50 years with physician-diagnosed asthma. All were receiving ICS therapy at British Thoracic Society (BTS) treatment steps 2 (up to 400µg budesonide equivalent [BDP] per day) or step 3 (up to 800µg BDP per day and additional long acting beta agonist [LABA]) – see Table 1 and Table E1. All participants gave informed consent.

The participant demographics and baseline characteristics were described by clinical history, 184 185 spirometry with reversibility by inhaled β₂ agonist according to ATS guidelines (EasyOne[®], ndd 186 Medical Technologies, Switzerland), fractional exhaled nitric oxide (Niox Vero[®], Circassia, UK), 187 and blood eosinophil count. Information was sought from primary care to confirm the medical 188 history, current treatment and allergies. At screening, all participants were provided a written asthma action plan, with a peak expiratory flow rate meter and diary (Mini Wright[®], Clement 189 190 and Clarke Limited, UK). Exclusion criteria included: forced expiratory volume less than 70% 191 predicted after salbutamol; more than 1 exacerbation in the preceding year; treatment with 192 antibiotics or oral steroids in the preceding 4 weeks (full list of exclusion criteria in Table E2). 193 Inoculation was performed as previously described ¹⁴ ¹⁸, by instillation of 80,000 colony-194 forming units (CFU) Streptococcus pneumoniae serotype 6B in 100µL saline into each nostril. 195 This strain has been previously used for challenge by us and others with reproducible carriage 196 rates, is fully sequenced, amoxicillin-sensitive, and does not cause any natural colonisation in 197 Liverpool ^{14, 15, 18}. Follow-up visit schedules are described in Figure E1, and nasal sampling was performed as described for previous studies ^{14, 15, 19}. 198

Participants were contacted daily for the first 7 days to report their peak flow and temperature. They maintained a peak flow diary and symptom log and were advised to follow their personal asthma action plan. At study completion, a 3 day-course of amoxycillin was prescribed for participants who remained colonised at either of the last 2 visits.

For microbiological and immunological comparison we used age-matched healthy controls from an influenza vaccine study (Sep 2015- Mar 2017), with identical methods and sampling, except that influenza-study participants received intramuscular tetravalent inactivated influenza vaccine either 3 days before or after inoculation with pneumococcus ²⁰. A subset of colonised asthmatic individuals (n=12) were re-challenged following the same protocol 6-11 months after the initial inoculation event.

209 Ethical approvals

Ethical Approval was obtained from the Liverpool East NHS Research Ethics Committee (reference number NW/016/0124). The study was co-sponsored by the Royal Liverpool University Hospital and the Liverpool School of Tropical Medicine. International Randomised Controlled Trial Number (ISRCTN) 16755478). Control group was obtained from the study approved under Liverpool East NHS Research Ethics Committee (EudraCT 2014-004634-26)

215 Flow cytometry analysis

Nasal: Nasal cells were collected by scraping the inferior turbinate of volunteers consecutively with two curettes (Rhino-pro[®], Arlington Scientific), as described before ¹⁹. Curettes were collected into PBS + 5mM EDTA and 0.5% heat inactivated FBS. Cells were dislodged from curettes by pipetting up and down and immunophenotyping of nasal cells was performed as previously described ^{9, 19}. Briefly, cellular samples were stained on ice for 15 minutes with LIVE/DEAD[®] Fixable Violet Dead Cell Stain (Thermofisher[®]), followed by staining for 15

222 minutes on ice with an antibody cocktail containing Epcam-PE, HLADR-PECy7, CD66b-FITC (all 223 Biolegend[®]), CD3-APCH7 (BD Biosciences[®]) or CD3-APCCy7 (Biolegend[®]), CD14-PercpCy5.5 224 (BD Biosciences[®]) and CD45-PACOrange (ThermoFisher[®]). Some samples were additionally stained concurrently with BDCA2-APC (Miltenyi®) and/or CD16-APC, CD1c-PE/Dazzle594, 225 226 CD19-BV650, CD4-BV605, CD8-BV785, TCRva7.2-PE/Dazzle594, TCRva7.2-BV711, CD123-227 BV711 and/or CD117–BV650 (all Biolegend[®]). Cells were washed at the end of incubation with 3mL PBS and filtered through a 70µm mesh (ThermoFisher[®]). After centrifugation for 5 228 229 minutes at 450xg, pellets were resuspended in 200µL CellFIX[™] (BD Biosciences[®]) and kept on 230 ice until sample acquisition. Flow cytometry data were acquired on a LSRII cytometer (BD), and analysed using Flowjo X (Treestar®). Compensation matrices were set using 231 compensation beads (Thermofisher[®]). All antibodies were titrated and fluorescence minus 232 one controls were used to verify specificity of signal for each of the antibodies included for at 233 234 least two samples. Samples with fewer than 500 immune cells or 250 epithelial cells were 235 excluded from analysis. To adjust for variable amount of cells collected between curettages, 236 we analysed both absolute cell counts and cell counts normalized to number of epithelial 237 cells. This has the advantage that an increase or decrease of certain immune populations does 238 not affect frequencies of other immune populations.

Peripheral Blood: To stain cells, PBMCs were thawed with 50 µg/mL DNAse I (MilliporeSigma)
in prewarmed RPMI containing 10% FBS and washed once in media including DNAse I. Briefly,
cellular samples were stained for 15 minutes with LIVE/DEAD® Fixable Violet Dead Cell Stain
(Thermofisher®), followed by staining for 15 minutes with an antibody cocktail containing
CD38-FITC, CD7-PE, CD196-PEeFluor610, CD5-PECy7 (all from ThermoFisher®), CD161-APC
(BD Biosciences®), CD4-PerPCy5.5, CD3-APCCy7, CD8-AlexaFluor700, CD45-BV510, CD69-

245	BV650 and TCRVα7.2-BV786 (all from Biolegend®). Finally, cells were washed, resuspended in
246	$200\mu L$ PBS, and acquired. Flow cytometry data were acquired on a LSRII cytometer (BD), and
247	analysed using Flowjo X (Treestar [®]). Compensation matrices were set using compensation
248	beads (Thermofisher ®).

249 Mucosal cytokine levels

Concentrated nasal lining fluid was collected by applying synthetic absorptive matrices to the nasal mucosa for 1 minute and stored at -80°C until analysis ²¹. Fluid was eluted by adding 100μL Luminex assay buffer, supernatant was clarified by centrifugation for 10 minutes, and 30 cytokines and immune proteins were analysed as per manufacturer's protocol as we previously described ^{9, 19}.

255 Antibody titres

256 Titres of antibodies against pneumococcal capsule and proteins were measured as previously described ¹⁵. Briefly, ELISA plates were coated with 6B polysaccharide at 4°C overnight and 257 258 washed 3 times. Absorption buffer was used for blanks, and to generate standards through 259 serial dilution of 89SF. Samples were diluted 1 in 100, and assayed in duplicate. After loading, 260 plates were incubated at room temperature for 2 hours, washed 3 times in washing buffer, 261 and secondary antibody applied and incubated for 90 minutes. Following 3 further washes, 262 plates were incubated in the dark with 100µl/well of para-nitrophenyl phosphate, and 263 absorbance measured at 405nm. Samples with coefficient of variation>15% between 264 duplicates were repeated and one sample due to a very high signal (outside standard curve) 265 was repeated using a 1 in 800 dilutions.

266 MSD: In a WHO reference lab, ELISA plates were coated with proteins by MSD. Standards 267 were prepared using 007sp in an initial 1:100 dilution with subsequent four-fold serial dilution. Samples were diluted 1:100, and assayed in duplicate with quality control (QC) sera
at 1:1000 and 1:2000 dilutions. Reactions were stopped by agitating with 150µL/well blocking
solution (5% BSA 1xPBS) at 700rpm for 1 hour at room temperature. After 4 washes,
detection antibody was added for a further 1 hour on the shaker, before a final wash and
immediate reading.on a MSD imager.

273 Statistical Analysis

SPSS version 22, R 3.5.0 and Graphpad prism version 5 were used for analysis. Area under the bacterial density-time curve were calculated by trapezoid method of log₁₀ (value+0.01). Colonisation rates were compared by chi-square test, and continuous measures by Mann-Whitney U test and independent samples T-test for non-normal distributed and normal distributed data, respectively. Spearman and Wilcoxon tests were used for correlation and paired-sample analysis respectively. All tests were two-tailed, with significance level of p<0.05.</p>

281 Primary End Point and Sample Size Calculation

The primary end-point was the experimental colonisation rate in asthmatics compared to healthy controls. Experimental colonisation was defined as positive bacterial culture from nasal wash at any point after inoculation until the end of follow-up. A sample size of 52 was estimated from historic challenge study data in healthy volunteers (colonisation rate 49.6%) and assuming 50% reduction in colonisation rate in people with asthma (i.e. absolute risk difference 24.6%).

288

289 **Results**

290 A total of 95 volunteers were consented, of which 50 were subsequently inoculated with 291 Streptococcus pneumoniae 6B (Figure E2). Reasons for exclusion are described in detail in 292 Figure E2, the commonest being lack of ICS therapy. Median age in the asthma and control 293 groups was 22 years [IQR 20-26] and 20 years [IQR 19-22] respectively (Table 3). 38 (76%) 294 asthma participants and 82 (54%) controls were female (Table 1-3). No serious adverse events 295 occurred. Median baseline blood eosinophil count was 0.2 [IQR 0.1-0.4], with median FEV1% 296 predicted 95% [91-100], median FeNO 25.5 [13.8-49.2] and asthma control (ACT) score 22 [20-24] (ACT 25 point scale – score 20-24 well controlled, less than 20 not well controlled). 297 298 Comparing individuals receiving step 2 and 3 treatment, there was no difference in blood 299 eosinophils (p=0.596) and FeNO (p=0.936), or control as measured by Asthma Control Test 300 (p=0.278) (Table 1). There was a positive correlation between FeNO levels and blood

301 eosinophil levels (p<0.0001, r=0.573).

302 Determinants of colonisation in asthma

303 Participants who were colonised (positive bacterial culture from nasal wash at any time point) 304 and non-colonised (negative bacterial culture from nasal wash at all time points) had similar 305 baseline characteristics (Table 2). One participant was colonised at baseline with S. 306 pneumoniae serotype 9, and subsequently became experimentally colonised with 6B, with 307 both serotypes identified at one time point. Body mass index (BMI) was higher in colonised 308 than in non-colonised participants (median 24.7 [IQR 24.1-29.0] and 23.5 [20.1-26.4] 309 respectively, p=0.019). FeNO levels were not significantly different at baseline (colonised 310 participants median 20.5 [IQR 13.5-37.5] vs non-colonised participants 29.5 [IQR13.5-54.75], 311 p=0.287).

312 Experimental pneumococcal colonisation in asthmatics vs healthy controls

The median inoculation dose per nostril was 78,834 CFU [IQR 76,333-84,167] for healthy controls compared to people with asthma 83417 CFU [78,333-85,292]. Table 3 for demographics.

Experimental colonisation rates were not significantly different in people with asthma compared with healthy controls (28/50 [56%] vs.68/151 [45%] respectively, p=0.17). The pneumococcal density as calculated by the area under the density-time curve was also similar in the two groups (Figure 1A-E). However, the duration of colonisation was decreased in asthmatics compared to healthy controls (median 14 days vs 29 days, p=0.034) (Figure 1F). The area under the density-time curves were similar in asthmatics regardless of the dose of ICS (>400 µg BDP) and BMI>25) (Figure 2A-D).

323 Homologous rechallenge of asthmatic individuals

We have reported complete protection in healthy controls against recolonisation with the same 6B strain up to 1 year after initial experimental colonisation (n=10) ¹⁵. To test this in asthma, twelve colonised individuals were re-challenged with the same strain 6-11 months after the first inoculation. Of these, four became recolonised (33.3%), which is notsignificantly different from the 56% colonisation rate during the primary challenge (relative risk 59.5%, 95% CI: 25.8-138%, p=0.20 with Fisher Exact test).

Within the limitation of our sample size, the density of the second colonisation episode did not appear substantially different from the first (Figure 3A). Of these four individuals, three cleared colonisation within 14 days of the re-challenge.

333 Pneumococcal antibody titres before and after colonisation

In healthy controls, antibody titres against pneumococcal proteins and capsule increase 334 following 6B experimental pneumococcal colonisation, but baseline titres do not predict of 335 336 risk of subsequent acquisition. To assess this in asthma individuals, we measured IgG titres in serum against 6B polysaccharide and 27 pneumococcal proteins at baseline and day 29 post 337 338 inoculation (Figure 3B-D). Anti-capsular antibody levels increased upon colonisation in 339 asthmatic individuals (median 3-fold increase, p = 0.0039 paired t-test). However, baseline 340 titres were not significantly different between individuals who became colonised and those who did not. Similarly, at baseline, there were no significant differences in IgG titres against 341 342 any of 27 pneumococcal protein between colonised and non-colonised individuals (Figure 3C). 343 Antibodies against 10 pneumococcal proteins were significantly induced by colonisation, 344 including antibodies against PspC, PspA and PiuA (Figure 3D).

345

346 Nasal cell populations in people with asthma and healthy controls before colonisation 347 To understand differences in immune populations underlying the altered dynamics of 348 pneumococcal colonisation in individuals with asthma, we performed phenotyping of nasal 349 immune cells using flow cytometry and minimally-invasive nasal curettes (Figure E3). Nasal 350 eosinophil frequency was similar in people with well controlled asthma and healthy controls 351 (Figure 4A and E3B), with a modest positive correlation with circulating blood eosinophil 352 levels in people with asthma (r=0.36, p=0.03, Figure 4B). Nasal neutrophil frequency was 353 lower in people with asthma compared to healthy controls (median neutrophil/epithelial cell 354 ratio 0.35 [0.038-2.75] vs 1.72 [IQR 0.75-4.43], p=0.0054, Figure 4C and E3C). A similar pattern 355 was seen in CD3⁺ T cells (median T/epithelial cell ratio 0.079 [0.034-0.32] and 0.36 [0.17-0.89]

356 in asthma and healthy controls respectively, p<0.0001, Figure 4D and E3D). MAIT cells were 357 specifically decreased among T cells in people with asthma (median proportion of total CD8⁺ 358 T cells 9.4% [IQR 5.0-13.3]) compared to healthy controls (median 15.8% [IQR 9.9-25.9], 359 p=0.0047, Figure 3E). Nasal MAIT levels correlated negatively with BMI (r = -0.38, p=0.023, 360 Figure 4F). Systemic MAIT cells are associated with protection against pneumococcal 361 colonisation ²², we analysed MAIT cells in blood of individuals with and without asthma (Figure E4). Blood MAIT cells were not different in healthy and asthma individuals (Figure 4G). 362 363 MAIT cell frequency was increased at baseline in healthy individuals that were protected 364 compared to susceptible individuals (p=0.026); there was no difference between colonised and non-colonised asthma individuals. 365

366 Changes in nasal cell populations after colonisation

367 There was a trend towards recruitment of monocytes at day +9 post colonisation compared to baseline in people with asthma (median fold change (FC)= 3.84, [IQR 1.15-9.38], p=0.055). 368 369 This effect of colonisation was also present in healthy controls (median FC= 3.63, [IQR 1.24-370 11.43], p=0.002, Figure 5A, B). Monocyte levels remained increased at day+29 in both people with asthma (median FC=2.23 [IQR 1.50-4.25], p=0.03) and healthy controls (median FC=1.72 371 372 [IQR 0.35-11.43], p=0.049). Evidence for monocyte recruitment persisted after normalising to 373 epithelial cells to correct for micro biopsy size (Figure 5C, D). CD66b⁺ granulocytes were 374 significantly increased in people with asthma at day+9 (median FC=1.78, [IQR 1.09-8.06], 375 p=0.044), but were no longer significantly increased at day+29 (median FC=1.84, [IQR 0.88-376 5.04], p=0.17, Figure 5E). In healthy controls, granulocytes were increased at day+7 (median FC=3.17, [IQR 1.05-7.37], p=0.009), returning to baseline levels at day+28 (median FC=1.03, 377 378 [IQR 0.41-3.05], p=0.89, Figure 5F). Contraty to monocytes, In subgroup analysis, neither

379 eosinophils or neutrophils were significantly recruited, although there was a trend for both 380 increased neutrophils (median FC=1.6) and eosinophils (median FC=2.0) at day 9 in asthmatics 381 (Figure E5). After correction to the total number of epithelial cells, these transient increases 382 in nasal granulocyte numbers were not significant, although there was still a tendency to 383 increased granulocyte numbers at day+9 in people with asthma (median FC=1.90) and healthy 384 controls (median FC=2.07) (Figure 5G, H). No changes in monocytes and granulocytes were observed after challenge in non-colonised subjects in either asthma or healthy control 385 386 cohorts.

Nasal cytokines during experimental colonisation in asthmatic and healthy individuals 387 388 We observed reduced populations of neutrophils and T cells in asthmatics at baseline (Table 389 2). Following colonisation, there was no evidence of excessive infiltration of inflammatory 390 cells (Figure 4) or increase in FeNO levels (Table 2). We therefore characterized nasal 391 inflammation in more detail by analysing nasal lining fluid for 30 cytokines and immune 392 proteins using multiplex detection (Luminex). Recapitulating the cell population data, we saw 393 mostly reduced cytokines in the nose of asthma compared to healthy individuals: 22/30 cytokines were significantly decreased (Figure 6A), and only anti-inflammatory IL-1RA 394 395 increased. Following inoculation, we did not see any increase in nasal cytokine levels in 396 asthma or healthy controls regardless of colonisation status (Figures 6B,C).

397

398 **Discussion**

This is the first study to examine controlled challenge of an infectious bacterium in people with well controlled asthma, providing a unique opportunity to study experimental nasopharyngeal colonisation and its relation to clinical characteristics. All participants had very well controlled physician diagnosed asthma and were taking inhaled corticosteroids.

403 Experimental colonisation rates and density were not significantly higher in people with well 404 controlled asthma on ICS therapy compared to healthy controls. However, a major difference 405 to healthy comtrols is that colonisation conferred less protection to homologous re-challenge, 406 although our sample size for re-challenge (n=12) is insufficient to determine the exact rate of 407 protection. In previous cross-sectional observational studies, high colonisation rates in people with asthma were reported ⁴. Our observation that a colonisation episode in 408 409 asthmatics is not fully immunising could explain these higher rates. However, direct 410 translation of our results is limited as the cross-sectional data tend to have ill-defined 411 diagnosis (self-reporting), and limited background information on medication, control, clinical characteristics and smoking history. Other factors prevalent in the wider populations of 412 413 asthmatics may therefore influence colonisation rates, such as a high dose of ICS therapy, 414 sub-optimal control, or more severe disease.

Despite incomplete protection against re-challenge, colonisation increased systemic antibody titres against pneumococcal protein and capsule. This indicates that serum IgG is not protective against colonisation in asthma, and mirrors previous data from healthy adults in which anti-capsular memory B cells gave protection, but antibody titres did not ¹⁵.

Nasal neutrophils and T cells, including MAIT cells, were decreased in people with asthma compared to healthy controls. Decreased MAIT cells have been reported amongst T cells in blood and sputum of people with asthma on ICS therapy ¹¹. In contrast, reduced MAIT cells in this study were confined to the nasal mucosa as we did not see changes in systemic MAIT numbers in asthma compared to healthy individuals here. Studying a young cohort with wellcontrolled asthma may explain this.

The decreased immune frequencies of neutrophils and T cells were mirrored by decreased levels of cytokines in the nasal lining fluid of asthma individuals. Together this suggest a general immune-suppressive environment, possibly due to ICS therapy and is a reflection of the good asthma control in our participants.

After colonisation the mucosal cellular changes were similar in people with asthma and healthy controls with recruitment of monocytes and granulocytes to the nose. We have previously reported a recruitment of monocytes to the nose following colonisation in healthy volunteers ⁹ ; despite altered baseline nasal immune parameters, there is no impaired mucosal immune response to pneumococcal colonisation in people with asthma taking moderate doses of ICS.

We did not see significant inflammation following colonisation when measured by exhaled NO or cytokine levels. During exacerbations amongst children, pneumococcal carriage rates increase ²³. The fact that we did not see inflammation triggered by colonisation could be an indication that pneumococcal acquisition is secondary to asthma exacerbations. Alternative explanations are that our volunteers had good asthma control, or that colonisation responses differ between children and adults. The reduced colonisation duration in asthma compared to healthy individuals was unexpected and seems paradoxical to the lack of excessive

inflammation observed in asthmatic individuals. It is possible that other inflammatory or
epithelial markers that we did not explore in this study could underlie this difference in ability
to sustain or clear colonisation.

Within the asthma cohort, an increased BMI was associated with likelihood of experimental 445 446 colonisation, while other clinical characteristics, such as FeNO, blood eosinophils and 447 spirometry were not. Blood eosinophils and baseline FeNO levels correlated positively, as seen in previously ²⁴. There was also a positive correlation between nasal and blood 448 eosinophils. BMI has not been studied in the context of nasopharyngeal colonisation in 449 asthma, although obesity related asthma is a recognised phenotype ²⁵. Obesity may be a 450 consequence of corticosteroid treatment, although this is unlikely in our well-controlled 451 452 cohort, who required one or less course of oral steroids in the last 12 months. We do not have data on BMI in our healthy volunteers, therefore it is plausible that obesity may affect 453 454 nasopharyngeal colonisation independent of asthma.

The careful characterisation of people with asthma, age-matched healthy controls and controlled challenge are a strength of our study. For safety reasons, we were unable to include participants with severe asthma on high dose of ICS. This was a small study powered to detect experimental colonisation rates in people with asthma and not general differences within the population.

460 **Conclusion**

People with asthma had lower nasal neutrophil and T cell levels compared to healthy controls,
which was confirmed by lower levels of nasal cytokines. Asthma individuals had a shorter
duration of of nasopharyngeal colonisation when challenged with *S.pneumoniae*. The rate of

- 464 colonisation was higher with increasing BMI, but not different from controls. Colonisation in
- 465 asthma individuals had a limited immunizing effect to homologous re-challenge suggesting a
- 466 function immunological difference either due to asthma disease or treatment.

467 **Acknowledgements**

- 468 We would like to thank all volunteers for participating in this study and the National Institute
- 469 for Health Research (NIHR) Local Comprehensive Research Network for clinical support. We
- 470 are also grateful to the entire EHPC team and clinicians who provided on call clinical cover for
- 471 the study. Flow cytometry acquisition was performed on a BD LSR II cytometer funded by a
- 472 Wellcome Trust Multi-User Equipment Grant (104936/Z/14/Z)

477 **References**

478

479 1. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of 480 pneumonia in people with asthma: a case-control study. Chest 2013; 144:1788-94. Qian CJ, Coulombe J, Suissa S, Ernst P. Pneumonia risk in asthma patients using inhaled 481 2. 482 corticosteroids: a quasi-cohort study. British Journal of Clinical Pharmacology 2017; 483 83:2077-86. 484 3. O'Byrne PM, Pedersen S, Carlsson LG, Radner F, Thoren A, Peterson S, et al. Risks of 485 pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183:589-95. 486 487 4. Esposito S, Terranova L, Patria MF, Marseglia GL, Miraglia del Giudice M, Bodini A, et 488 al. Streptococcus pneumoniae colonisation in children and adolescents with asthma: 489 impact of the heptavalent pneumococcal conjugate vaccine and evaluation of 490 potential effect of thirteen-valent pneumococcal conjugate vaccine. BMC Infectious 491 Diseases 2015; 16:12. 492 5. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, et al. A 493 longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage 494 in a UK setting. Epidemiol Infect 2005; 133:891-8. 495 6. Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I, Carandell E, et al. New evidence of 496 risk factors for community-acquired pneumonia: a population-based study. Eur Respir 497 J 2008; 31:1274-84. 498 7. Zaidi SR, Blakey JD. Why are people with asthma susceptible to pneumonia? A review 499 of factors related to upper airway bacteria. Respirology 2019; 24:423-30. 500 Jounio U, Juvonen R, Bloigu A, Silvennoinen-Kassinen S, Kaijalainen T, Kauma H, et al. 8. 501 Pneumococcal carriage is more common in asthmatic than in non-asthmatic young 502 men. The Clinical Respiratory Journal 2010; 4:222-9. 503 9. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation 504 induced by influenza virus impairs human innate immune control of pneumococcus. 505 Nature Immunology 2018; 19:1299-308. 506 Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA. Asthma as a 10. 507 risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352. 508 Hinks TSC. Mucosal-associated invariant T cells in autoimmunity, immune-mediated 11. 509 diseases and airways disease. Immunology 2016; 148:1-12. 510 12. Melo JT, Jr., Tunstall T, Pizzichini MMM, Maurici R, Rocha CC, Dal-Pizzol F, et al. IL-5 511 Levels in Nasosorption and Sputosorption Correlate with Sputum Eosinophilia in 512 Allergic Asthma. Am J Respir Crit Care Med 2019; 199:240-3. Hansel TT, Johnston SL, Openshaw PJ. Microbes and mucosal immune responses in 513 13. 514 asthma. Lancet 2013; 381:861-73. 515 Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, et al. First 14. human challenge testing of a pneumococcal vaccine. Double-blind randomized 516 517 controlled trial. Am J Respir Crit Care Med 2015; 192:853-8. 518 15. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, et al. Controlled 519 human infection and rechallenge with Streptococcus pneumoniae reveals the

- 520 protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013; 521 187:855-64.
- 52216.Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;523368:804-13.
- 524 17. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015; 16:45-56.
- 525 18. Au Gritzfeld JF, Au Wright AD, Au Collins AM, Au Pennington SH, Au Wright AKA,
 526 Au Kadioglu A, et al. Experimental Human Pneumococcal Carriage. JoVE
 527 2013:e50115.
- Jochems SP, Piddock K, Rylance J, Adler H, Carniel BF, Collins A, et al. Novel Analysis of
 Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for
 Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash. PLOS
 ONE 2017; 12:e0169805.
- 53220.Rylance J, de Steenhuijsen Piters WA, Pojar S, Nikolaou E, German E, Mitsi E, et al.533Effect of Live Attenuated Influenza Vaccine on Pneumococcal Carriage. bioRxiv5342018:343319.
- Au Thwaites RS, Au Jarvis HC, Au Singh N, Au Jha A, Au Pritchard A, Au Fan H,
 et al. Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human
 Respiratory Mucosa and Laboratory Processing of Samples. JoVE 2018:e56413.
- Jochems SP, de Ruiter K, Solórzano C, Voskamp A, Mitsi E, Nikolaou E, et al. Innate and
 adaptive nasal mucosal immune responses following experimental human
 pneumococcal colonization. The Journal of Clinical Investigation 2019; 129:4523-38.
- Zhou Y, Jackson D, Bacharier LB, Mauger D, Boushey H, Castro M, et al. The upperairway microbiota and loss of asthma control among asthmatic children. Nature
 Communications 2019; 10:5714.
- Silvestri M, Sabatini F, Sale R, Defilippi A-C, Fregonese L, Battistini E, et al. Correlations
 between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction
 reversibility in childhood asthma are detectable only in atopic individuals. Pediatric
 Pulmonology 2003; 35:358-63.
- 54825.Peters U, Dixon AE, Forno E. Obesity and asthma. Journal of Allergy and Clinical549Immunology 2018; 141:1169-79.
- 550 26. SIGN/BTS. SIGN 153 British guideline on the management of asthma. 2016.
- 551

552

554 Tables

555 Table 1: Demographics and clinical characteristics for the asthma cohort according to

556 BTS treatment step

	Whole Group	BTS Step 2	BTS Step 3	P value
Total participants n (%)	50	36 (72)	14 (28)	
Age (years) median (IQR) [*]	22 (19.0-26.0)	21 (19.0-25.0)	22(19.0-27.0)	0.632
Gender Female n (%) [†]	38 (76)	28 (77.7)	10 (71.4)	0.637
BMI (kg/m2) Mean (95 CI, SD) [‡]	24.6 (21.6-27.5)	25.3 (23.1 - 27.6, 6.7)	24.9 (22.9 - 26.8, 3.3)	0.821
Blood eosinophils Median (IQR) [*]	0.2 (0.1-0.4)	0.2 (0.1-0.4)	0.3 (0.1-0.4)	0.596
FEV1% predicted Mean (95 CI, SD) [‡]	95 (13.28)	95 (91-100, 13.48)	94 (86-101,13.19)	0.752
FeNO-ppb baseline Median (IQR) [*]	25.5 (13.8-49.2)	27 (12.0-50.5)	20.5 (14.8-49.2)	0.936
PEFR variability% Median (IQR) [*]	14.6 (9.6-21.1)	14.3 (9.5-21.9)	14.8 (10.0-26.7)	0.756
ACT score baseline Median (IQR) [*]	22 (20-24)	22 (20-24)	22(20-23)	0.278
Inhaled Corticosteroid (µg) median (IQR) [*]	400 (400-400)	400 (400-400)	450 (400-800)	0.001
Colonisation status n (%) [†]	28 (56%)	19 (53%)	9 (64%)	0.462

⁵⁵⁷ 558

558 BTS Treatment Steps are part of the British Thoracic Society (BTS) guidelines on management of asthma, where treatment is increased in stepwise manner -starting from short acting beta agonist at step 1, to oral steroids at step 5. These are described in online supplement Table

560 E2. *Mann Whitney U Test, [†]Pearson chi square, [‡]Independent Samples T test

562 Table 2 Demographics and clinical characteristics for the asthma cohort according to

563 colonisation status

	Whole Group	Colonised	Non-Colonised	p value
Number of Participants	50	28 (56)	22 (44)	n/a
Age (years)	22 (19.8-26.0)	22 (20-26)	21(19-24)	0.432
median (IQR) [*]				
Gender Female n (%) ⁺	38 (76)	23(82)	15(68)	0.251
BMI (kg/m2)	24.6 (21.6-27.5)	24.7 (24.1-29.0)	23.5 (20.1-26.4)	0.019
Median (IQR) [‡]				
Blood eosinophils	0.2 (0.1-0.4)	0.2 (0.1-0.45)	0.25 (0.1-0.4)	0.933
Median (IQR) *				
[§] Blood Eosinophils >0.3 n	n/a	16 (59%)	11 (41%)	0.615
(%) [†]				
FEV1% predicted	95.5 (87.5-105)	98.5 (88.25-105)	94.5 (84.5-103.5)	0.340
Median (IQR) [‡]				
PEFR variability >12% [‡]		15 (62.5%)	13 (72%)	0.508
FeNO-ppb baseline	25.5 (13.75-49.25)	20.5 (13.5-37.5)	29.5 (13.5-54.75)	0.287
Median (IQR) *				
FeNO ppb	25 (11-41.5)	25 (10-37)	26.5 (13.75- 54.75)	0.526
Day 7 median (IQR) *				
"FeNO >40 ppb n** (%) ⁺	n/a	6 (37.5%)	10 (62.5%)	0.071
ACT score baseline	22 (20.75-24)	22 (20.25-24)	22 (20.75-24)	0.129
Median (IQR) [‡]				
ACT score Day 29 median	22 (21-24)	22 (22-24)	22.5 (22-24)	0.816
(IQR) [‡]				
Inhaled Corticosteroid (µg)	400 (400-400)	400 (400-500)	400 (350-400)	0.208
median (IQR) *				

⁵⁶⁴ 565

* Mann Whitney U Test, † Pearson chi square, ‡ Independent Samples T test, ^{\$} missing values

**n = number of participants with a raised FeNO in each cohort. "Pearson's chi square p=0.071 for a raised FeNO of >40 at baseline for colonisation and for change in FeNO from baseline * Pearson's chi square p=0.367.

568 [§]Pearson's Chi square p=0.615 for a raised eosinophil count of >0.3 at baseline, Pearson's chi square test p=0.274 for colonisation positive with steroid dose >400μg, and for steroid dose >500μg p=0.288

571 Table 3 Colonisation rates in people with asthma compared to healthy control

	Asthma	Healthy Control	P value
	(N=50)	(N=151)	
Demographics			
Median age (range) – year	22 (20-26)	20 (19-22)	<.0005*
Female – no. (%)	38 (76)	82 (54.3)	<0.007*
Median dose (range) – CFU/nostril	83417 (78333-85292)	78834 (76333-84167)	<0.001*
Colonisation Status positive any timepoint– no (%)	28 (56)	68 (45)	0.178+
Colonisation Status positive – day 2 (%)	19 (38)	61 (40)	0.764+
Colonisation Status positive – day 7 (%)	22 (44)	62(41)	0.715+
Colonisation Status positive – day 9 (%)	17 (34)	60 (40)	0.470+
Colonisation Status positive – day 14 (%)	19 (38)	50 (33)	0.528+
Colonisation Status positive – day 22 (%)	12 (24)	43 (28)	0.538+
Colonisation Status positive – day 29 (%)	11 (22)	34 (23)	0.939+
Duration days median (range)	14 (7-29)	29 (14-29)	0.034*
Colonisation Density log transformed AUC (cfu/ml) median (range)	63.49 (14.04-116.3)	81.18 (48.15-104.5)	0.060*

572

573 *Mann Whitney U Test, *Pearson chi square

575 Figure Legends

576 Figure 1: Pneumococcal densities in people with asthma and healthy controls A-C. Area under 577 log-transformed bacterial colonisation density curve for participants colonised (positive 578 bacterial culture from nasal wash) with pneumococcus at any time point who attended all 579 visits up to A) day 14 (n=asthma 27, healthy control (HC) 67), B) up to day 22 (n= 27 asthma, 580 57 HC) and C) up to day 29 (n=27 asthma, 59 HC). Individual volunteers are shown, and the 581 lines represent median and inter-quartile range p values for Mann Whitney U Test are shown. 582 D-E: Bacterial colonisation density at each time point; D) all positive participants (positive bacterial culture from nasal wash at any time point) with negative time points included 583 584 (participants attended the visit and the nasal wash sample was negative for bacterial culture) 585 (n=28 asthma, 68 HC), E) all positive participants at any timepoint with negative values 586 removed (asthma n=19, 22, 17,19, 12, 11 at days 2, 7, 9, 14, 22,29 respectively, HC n=61, 62, 587 60, 50, 43, 35 at days 2, 7, 9, 14, 22 and 29. Values are mean and 95% confidence interval for log transformed densities at each time point + 0.01 added to all values to allow log 588 589 transformation). F) Cumulative clearance of colonisation (first time point when nasal wash 590 was negative for bacterial culture following a positive result at an earlier time point) in asthma 591 vs HC at each time point. Clearance rates at each time point for asthma and HC

593	Figure 2: Bacterial colonisation density for asthmatics. A) dose of inhaled corticosteroid (ICS)
594	>400µg n=7 or =<400µg n=21, all colonised (nasal wash positive for bacterial culture at any
595	time point) participants with negative time points (nasal wash negative for bacterial culture
596	at a specific timepoint) included. B) ICS dose >400µg or <400µg all colonised participants with
597	negative time points removed. C) stratification by body mass index (BMI) >25 n=12, <25 n=16,
598	all colonised participants with negative time points included. D) BMI >25 or <25, all colonised
599	participants with negative time points removed. Values are log transformed, bars represent
600	mean and 95% confidence interval.

602 Figure 3: Immunising effect of colonisation in asthmatic individuals. A) Bacterial colonisation 603 density during challenge and re-challenge. Log transformed densities at each timepoint are 604 shown. The mean value of log-transformed colonisation density during the primary 605 colonisation episode for all asthma individuals is depicted by a grey line (as found in Figure 606 1D). The four individuals that were positive upon re-challenge are depicted. Only densities for 607 positive nasal washes are shown and re-challenge samples per volunteer are indicated by an R after their ID. For the re-challenge phase, samples were only collected up to day 14, 608 609 indicated by a dashed line. B) Anti-6B polysaccharide IgG titres were measured in serum of asthmatic individuals before and after challenge, stratified by colonisation status. ** p = 0.004 610 611 by paired t-test. C) Baseline levels of IgG titres against 27 pneumococcal proteins measured 612 by multiplex. Mean and 95% confidence intervals are shown for colonised (grey) and non-613 colonised (white) asthmatic individuals. D) Anti-protein IgG titres depicted as log₂ fold-change 614 to baseline, with individuals stratified by colonisation status. Mean and 95% confidence 615 interverals are shown. Red bars depict proteins against which titres were significantly 616 different following colonisation compared to baseline (p<0.05 by paired t-test, corrected for 617 multiple testing using Benjamini-Hochberg).

619 Figure 4: Nasal immune profiles in asthma (closed circles) and healthy control (closed squares) 620 at baseline. Levels of A) eosinophils normalized to epithelial cells for people with asthma and 621 healthy controls. Symbols represent individuals, with superimposed group median and IQR, 622 and. B) Correlation by linear regression between blood eosinophils (x1000/µL blood) and nasal eosinophils (Spearman rank test). Levels of C) neutrophils and D) CD3+ T cells 623 624 normalized to epithelial cells for asthmatics and healthy controls (HC). Student t-tests were performed after normalisation by log-transformation data. E) Percentage of mucosal 625 associated invariant T cells (MAIT) amongst nasal CD8+ T cells. Median and IQR are 626 627 superimposed. and symbols represent individual volunteers. Student t-test was used. F) Linear correlation between body mass index (BMI) and MAIT cell frequency. (Spearman rank 628 629 test). G) Levels of MAIT cells among blood CD8+ T cells at baseline in asthmatics and healthy 630 donors. Mann-Whitney tests were used to compare colonisation status for healthy controls 631 or asthmatics as data were not normally-distributed.

633 Figure 5. Longitudinal measurements of monocytes and neutrophils in nasal mucosa following 634 pneumococcal challenge. Baseline-normalized levels of monocyte numbers in A) asthma and B) healthy control, and monocyte levels normalized to epithelial cells for C) asthma and D) 635 636 healthy control. Baseline-normalized levels of granulocyte numbers in E) asthma and F) 637 healthy control and granulocyte numbers normalized to epithelial cells for G) asthma and H) 638 healthy control are shown. Tukey boxplots are presented as well as results from paired-639 Wilcoxon rank tests compared to baseline levels (comparing the change from baseline to the 640 days 7, 9, and 29 as shown); FC= Fold Change, Spn = S. pneumoniae).

642	Figure 6. Nasal lining fluid cytokine analysis. A) Baseline levels of 30 cytokines for asthmatics
643	(A, grey) and healthy donors (HD, white). Significantly different cytokines are indicated in red,
644	while non-significant cytokines in white. Based on t-test on log-transformed values, followed
645	by Benjamini-Hochberg correction for multiple testing with cut-off of $p = 0.01$. Boxplots are
646	shown per group. B) Asthmatic (n=55, 26 of whom were colonised) and C) healthy donor
647	(n=63, 30 of whom were colonised) heatmaps over time following inoculation. The mean log2
648	fold-change compared to baseline per group is shown per day and per cytokine, stratified by
649	colonisation status. No significant changes were seen by paired t-test followed by Benjamini-
650	Hochberg multiple testing correction.
651	
652	
653	
654	
655	
656	
657	
658	



Figure 1



Figure 2





Figure 3 667



Figure 4





673 Figure 5



675

676 Figure 6

678 Online Data Supplement

679 Table E1: British Thoracic Society Treatment steps ²⁶: shaded area represent the cohort of patients recruited for the study

BTS Treatment Step

1	Mild intermittent asthma	Inhaled short acting $\beta 2$
		(SABA)agonist as required
2	Regular Preventer Therapy	SABA +
		• Inhaled
		Corticosteroids (ICS) 200-
		400 µg
3	Initial add-on therapy	SABA+
		 Add in inhaled long acting β₂ agonist (LABA) Increase ICS up to 800µg Consider other therapies – Leukotriene receptor antagonists (LRA) and slow release theophylline
4	Persistent poor-control	SABA+LABA
		• Increase ICS up to
		2000µg

	medRxiv preprint doi: https://doi.org/10.1101/2020.08.19.20177790; this version posted August 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.						
	5	Continuous or frequent use	SABA+LABA+2000µ	ug ICS			
		of oral steroids	• Regular	ICS	to		
			control symptoms				
680							
681							

All rights reserved. No reuse allowed without permission.

683 Table E2: Exclusion Criteria for EHPC Asthma

- 684
- Close physical contact with at-risk individuals (children under 5yrs, immunosuppressed adults)
- History of drug or alcohol abuse drinking over the recommended alcohol intake limit (more than 14 units of alcohol per week).
- Current Smokers or ex-smoker with a significant smoking history (>10 pack years)
- Taking medications that may affect the immune system e.g. oral steroids, steroid nasal spray, antibiotics, and disease-modifying antirheumatoid drugs.
- Any acute illness unexplained symptoms in the preceding 14 days.
- Having received any antibiotics, oral steroids or nasal steroid spray in the preceding 28 days
- More than 1 asthma exacerbation (as defined by ATS) in the last twelve months.
- Taking anticoagulants
- History of culture-proven pneumococcal disease
- Allergy to penicillin/amoxicillin
- Simultaneously involved in another clinical trial unless observational or in follow-up (noninterventional) phase.
- History of significant cardiorespiratory disease (excluding stable hypertension, and asthma at treatment step 2 and 3), or diseases associated with altered immunity, including diabetes, alcohol abuse, malignancy, rheumatological conditions
- Pregnancy
- Taking any medications except those on the "allowed list" (statins, anti-hypertensives, antidepressants, bisphosphonates, hormone replacement therapy, vitamin supplements, antiacid medications, nicotine replacement therapy (NRT), inhaled steroids up to 800 micrograms BDP equivalent, inhaled beta 2 agonists, leukotriene receptor antagonist



Figure E1: Study Overview: Study design showing timepoints for follow up visits. Participants were pre-screened up to 14 days before screen; at baseline full history, including relevant examination was done along with Spirometry, Peak Expiratory Flow Rate (PEFR), and baseline blood samples. Nasal wash was obtained for pneumococcal detection and nasal cells for immunophenotyping. *Only colonised participants. Fractional Exhaled Nitric Oxide (FeNO)



712 Figure E2: Recruitment: Flow chart showing recruitment and retention numbers. Reasons for 713 withdrawal: Not on inhaled corticosteroids (ICS) n=17, unable to contact after consent n=5, 714 medical placement n=2, ICS dose too high n=2, n=1 for each of the following: not using ICS as 715 prescribed, moved out of the area, no reason stated, personal reasons, high white cell count, 716 headaches daily, penicillin allergy, bronchiectasis, using non-invasive ventilation, withdrew 717 consent, >3 exacerbations in the preceding 12 months, proven pneumococcal pneumonia. One 718 participant was excluded after day 2 as they had low peak expiratory flow rate (PEFR) and had 719 to increase ICS, thus exceeding the 800µg budesonide equivalent threshold.





722 Figure E3: Nasal cell phenotyping. A) Flow cytometry gating strategy for nasal cells from one representative participant with asthma. Numbers of acquired B) eosinophils, C) neutrophils 723 724 and D) T cells from the nose at baseline for asthmatic (grey) and healthy (black) donors. 725 Median and interquartile ranges are depicted, as well as results from student t-test on logtransformed data. 726





730 one representative participant with asthma.





Figure E5. Nasal neutrophil and eosinophil numbers. Baseline-normalized numbers of neutrophils in A) asthma and B) healthy control. Baseline-normalized numbers of eosinophils in C) asthma and D) healthy control. Tukey boxplots are presented as well as results from paired-Wilcoxon rank tests compared to baseline levels (comparing the change from baseline to the days 7, 9, and 29 as shown); FC= Fold Change, Spn = S. pneumoniae).



Figure 1



Figure 2







Figure 4



Figure 5





Figure 6